Frédéric Triebel, MD. Ph.D., is the scientific founder of Immutep S.A. (2001). Before starting Immutep, he was Professor in Immunology at Paris University. While working at Institut Gustave Roussy (IGR), a large cancer centre in Paris, he discovered the LAG-3 gene in 1990 and continued working on this research program since then, identifying the functions and medical usefulness of this molecule. He headed a research group at IGR while being also involved in the biological follow-up of cancer patients treated in Phase I/II immunotherapy trials. He was Director of an INSERM Unit from 1991 to 1996. First trained as a clinical haematologist, Dr. Triebel holds a Ph.D. in immunology (Paris University) and successfully developed several research programs in immunogenetics, leading to 145 publications and 18 patents. Dr. Triebel serves as the CSO/CMO of Immutep Limited, based in Sydney, Australia.
Mark Your Calendars Now!
Conference 29 - 31 October • Exhibition & Seminars 29 - 31 October